Sorafenib Tosylate Tablets

DRUG2 trials

Sponsors

Beijing Shenogen Biomedical Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Advanced Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma (HCC)

Phase 3

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

TerminatedNCT03236649

Beijing Shenogen Biomedical Co., LtdHepatocellular Carcinoma (HCC)

Start: 2017-09-20End: 2022-02-08Updated: 2023-02-08

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruitingNCT04344158

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Hepatocellular Carcinoma (HCC)

Start: 2020-08-11End: 2026-12-31Target: 648Updated: 2025-02-20

Related Papers

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

2025-05-0815 citations

Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study.

Journal of Clinical Oncology2021-01-201 citations

Icaritin inhibits PD‐L1 expression by Targeting Protein IκB Kinase α

European Journal of Immunology2020-12-2360 citations